导航菜单
Following China's 2026 "315 Gala" - the country's annual consumer rights program known for exposing market misconduct - the once-booming exosome trend in cosmetics and medical aesthetics has rapidly cooled in China.
But the real story is not the decline of a technology.
It is the correction of a market driven by aggressive commercialization, exaggerated claims, and increasingly blurred compliance boundaries.
As the industry moves beyond the hype cycle, exosomes in China are entering a new phase - one shaped less by marketing narratives and more by scientific validation, regulatory expectations, and long-term viability.
The recent scrutiny was not aimed at exosome technology itself, but at the growing number of compliance issues surrounding products marketed under the "exosome" label in China.
Investigations exposed problems ranging from unlicensed manufacturing and certificate misuse to misleading claims and unauthorized applications in medical aesthetic settings. In many cases, so-called "exosome products" lacked even basic compliance support, yet still entered the market through trend-driven branding and concept-based marketing.
At the same time, claims such as "ultimate repair" and "breakthrough anti-aging" were amplified far beyond current scientific evidence or regulatory allowances - creating not only consumer confusion, but also potential safety concerns.
From a regulatory perspective, China's current cosmetic framework already signals a cautious stance toward human-derived cells, tissues, and related substances in cosmetics. The broader issue, therefore, is not whether exosome technology itself is innovative, but whether the market has been commercializing the concept responsibly.
In this sense, the recent slowdown reflects less a rejection of biotechnology and more a broader market correction.
Globally, the regulatory environment for exosome applications in cosmetics remains highly uncertain - particularly for human-derived exosomes.
In China, no exosome-related ingredient has been included in the Inventory of Existing Cosmetic Ingredients in China (IECIC), and no exosome-based new cosmetic ingredient has been approved to date.
In the United States, exosome products intended for therapeutic purposes generally fall under FDA oversight, and there are currently no FDA-approved exosome products on the market. At the same time, some companies have begun exploring INCI name applications through the Personal Care Products Council (PCPC) as part of longer-term compliance planning.
The European Union continues to maintain strict restrictions on ingredients derived from human cells or tissues in cosmetics, while Japan and South Korea also apply cautious regulatory approaches to these types of materials under their respective cosmetic frameworks.
Taiwan (China) has taken a comparatively more flexible approach in recent years, introducing a conditional case-by-case review mechanism for human-derived exosomes in cosmetics in 2024 and further relaxing certain toxicological testing requirements in 2026.
Despite regional differences, the broader regulatory direction remains relatively consistent:
human-derived exosomes are still far from achieving large-scale compliant application in cosmetics.
As market enthusiasm fades, the industry may finally have room to focus on more fundamental questions.
Clearer regulatory signals help reduce opportunistic marketing and gray-market activities built around the exosome concept, while also creating more defined compliance boundaries for companies investing in legitimate R&D.
At the same time, exosome technology itself remains at an early stage of scientific and industrial development. Whether it can eventually support viable cosmetic applications will depend not only on efficacy claims, but also on advances in safety evaluation, manufacturing standards, quality control, and regulatory frameworks.
Ultimately, the long-term competition will not be driven by who markets exosomes most aggressively, but by who can build credible science and compliant technology behind them.
The recent crackdown should not be interpreted as a denial of emerging biotechnology itself. Rather, it reflects China's growing regulatory efforts to address irresponsible commercialization and restore clearer industry boundaries.
As the industry moves beyond hype, the future of exosome-related technologies in cosmetics will depend less on marketing narratives and more on scientific validation, responsible commercialization, and evolving regulatory expectations.
